文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

闭环氧控改善高流量鼻导管氧疗下急性低氧性呼吸衰竭患者的氧疗:HILOOP随机交叉研究

Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study).
PubMed 文献 · Crit Care · 2022-04-14
一句话结论单中心随机交叉研究显示,闭环氧控较手动滴定使中重度急性低氧性呼吸衰竭HFNO患者处于个体化最佳SpO2范围的时间比例从89%提高至96.5%,并减少每小时手动调节次数。

本研究为单中心、单盲、随机交叉研究,纳入45例接受HFNO(流量≥40 L/min且FiO2≥0.30)的中重度急性低氧性呼吸衰竭成人患者,随机先后接受4小时闭环氧控与4小时手动氧滴定。主要终点为处于个体化最佳SpO2范围的时间百分比,闭环氧控组为96.5%(93.5至98.9)%,手动滴定组为89%(77.4至95.9)%,差异估计10.4(95%CI 5.2至17.2),p<0.0001。闭环氧控还减少高于及低于最佳范围的时间、高于次优范围的时间以及每小时手动调节次数,两组SpO2<88%和<85%事件数无显著差异。作者认为闭环氧控改善了HFNO下中重度AHRF患者的氧疗并降低医护人员工作负荷,在氧供有限、医疗需求高的情境(如COVID-19大流行)中尤其有意义。

要点

  • 单中心随机交叉研究纳入45例HFNO(流量≥40 L/min、FiO2≥0.30)的中重度AHRF成人患者,闭环氧控组处于个体化最佳SpO2范围的时间为96.5%(93.5至98.9)%,手动滴定组为89%(77.4至95.9)%,p<0.0001,差异估计10.4(95%CI 5.2至17.2)。
  • 闭环氧控减少高于及低于最佳SpO2范围的时间,也减少高于次优范围的时间。
  • 闭环氧控所需每小时手动调节次数更少,可降低医护人员工作负荷。
  • 两组SpO2<88%和<85%事件数无显著差异。
  • 作者认为该结果在氧供有限、医疗需求高的情境(如COVID-19大流行)中尤其有意义。

适用人群与场景

  • 接受HFNO(流量≥40 L/min且FiO2≥0.30)的中重度急性低氧性呼吸衰竭成人患者。

诊断标准与关键阈值

  • HFNO条件:流量≥40 L/min且FiO2≥0.30。
  • 主要终点:处于个体化最佳SpO2范围的时间百分比。

处置流程与药物剂量

  • 随机先后接受4小时闭环氧控与4小时手动氧滴定,之后每例患者切换至另一种治疗。

研究设计与关键结果

  • 单中心、单盲、随机交叉研究,纳入45例中重度AHRF接受HFNO的成人患者,比较4小时闭环氧控与4小时手动氧滴定。
  • 主要终点:处于个体化最佳SpO2范围的时间百分比,闭环氧控组96.5(93.5至98.9)% vs 手动滴定组89(77.4至95.9)%,p<0.0001;差异估计10.4(95%CI 5.2至17.2)。
  • 闭环氧控期间处于次优范围(高于和低于最佳SpO2范围切点)的时间更少,高于次优范围的时间也更少。
  • 闭环氧控所需每小时手动调节次数更少。
  • SpO2<88%和<85%事件数两组间无显著差异。

证据类型、等级与局限

  • 证据类型:单中心、单盲、随机交叉研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为闭环氧控改善HFNO下中重度AHRF患者的氧疗,增加处于最佳氧合范围的时间并降低医护人员工作负荷;作者认为该结果在氧供有限、医疗需求高的情境(如COVID-19大流行)中尤其有意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We aimed to assess the efficacy of a closed-loop oxygen control in critically ill patients with moderate to severe acute hypoxemic respiratory failure (AHRF) treated with high flow nasal oxygen (HFNO).

METHODS: In this single-centre, single-blinded, randomized crossover study, adult patients with moderate to severe AHRF who were treated with HFNO (flow rate ≥ 40 L/min with FiO2 ≥ 0.30) were randomly assigned to start with a 4-h period of closed-loop oxygen control or 4-h period of manual oxygen titration, after which each patient was switched to the alternate therapy. The primary outcome was the percentage of time spent in the individualized optimal SpO2 range.

RESULTS: Forty-five patients were included. Patients spent more time in the optimal SpO2 range with closed-loop oxygen control compared with manual titrations of oxygen (96.5 [93.5 to 98.9] % vs. 89 [77.4 to 95.9] %; p < 0.0001) (difference estimate, 10.4 (95% confidence interval 5.2 to 17.2). Patients spent less time in the suboptimal range during closed-loop oxygen control, both above and below the cut-offs of the optimal SpO2 range, and less time above the suboptimal range. Fewer number of manual adjustments per hour were needed with closed-loop oxygen control. The number of events of SpO2 < 88% and < 85% were not significantly different between groups.

CONCLUSIONS: Closed-loop oxygen control improves oxygen administration in patients with moderate-to-severe AHRF treated with HFNO, increasing the percentage of time in the optimal oxygenation range and decreasing the workload of healthcare personnel. These results are especially relevant in a context of limited oxygen supply and high medical demand, such as the COVID-19 pandemic. Trial registration The HILOOP study was registered at www.

CLINICALTRIALS: gov under the identifier NCT04965844 .

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Roca O, Caritg O, Santafé M, et al. Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study). Crit Care. 2022. PMID: 35422002. doi:10.1186/s13054-022-03970-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。